Febuxostat;Febuxostat

Deutsche Medizinische Wochenschrift

Volumn 136, Issue 23, 2011, Pages 1270-1274

  Wittkopper K ^a   Emons, J ^a   El Armouche, A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

febuxostat; gout; uric acid; uricostatic drug; xanthine oxidase inhibitor

Indexed keywords

FEBUXOSTAT;

REVIEW;

ALLOPURINOL; ENZYME ACTIVATION; GOUT; GOUT SUPPRESSANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; URIC ACID; XANTHINE OXIDASE;

EID: 79958238210     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1272573     Document Type: Review

References (23)

1. Becker M A., Kisicki J, Khosravan R et al,. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004 23 1111-1116 (Pubitemid 39625877)
2. Becker M A., Schumacher H R., Espinoza L R. et al,. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010 12 R63
3. Becker M A., Schumacher Jr H R., Wortmann R L. et al,. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 353 2450-2461 (Pubitemid 41781828)
4. Becker M A., Schumacher Jr H R., Wortmann R L. et al,. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005 52 916-923 (Pubitemid 40372228)
5. Becker M A., Schumacher H R., MacDonald P A. et al,. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009 36 1273-1282
6. EMA. Adenuric. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000777/WC500021812.pdf Stand Mai 2008
7. Emmerson B T. The management of gout. N Engl J Med 1996 334 445-451 (Pubitemid 126528536)
8. Fachinformation. Allopurinol. Stand April 2009.
9. Fachinformation. Adenuric, Febuxostat. Stand Dez. 2009.
10. FDA/CDER. Med. Review Febuxostat. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2009/021856s000-MedR-P1.pdf bis http://www.accessdata.fda. gov/drugsatfda-docs/nda/2009/021856s000-MedR-P5.pdf Stand Dez. 2008
11. Lee H Y., Ariyasinghe J T., Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008 49 384-387 (Pubitemid 351716706)
12. Moreland L W. Febuxostat treatment for hyperuricemia and gout? N Engl J Med 2005 353 2505-2507
13. NICE. Febuxostat for the management of hyperuricaemia in people with gout. http://www.nice.org.uk/nicemedia/pdf/TA164Guidance.pdf Dez. 2008
14. Okamoto K, Eger B T., Nishino T et al,. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003 278 1848-1855 (Pubitemid 36801423)
15. Okamoto K, Matsumoto K, Hille R et al,. The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A 2004 101 7931-7936 (Pubitemid 38698031)
16. Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch 2008 75 2-3 (Pubitemid 351303851)
17. Reinders M K., Haagsma C, Jansen T L. et al,. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300600mg/day versus benzbromarone 100200mg/day in patients with gout. Ann Rheum Dis 2009 68 892-897
18. Schumacher Jr H R. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005 14 893-903
19. Schumacher Jr H R., Becker M A., Lloyd E et al,. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009 48 188-194
20. Schumacher Jr H R., Becker M A., Wortmann R L. et al,. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008 59 1540-1548
21. Takeda. US-amerikanische Produktinformation Uloric (Febuxostat). Stand Feb. 2009.
22. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010 6 30-38
23. Yu K H. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007 1 69-75